Topic of the quarter: Many recent news articles have highlighted the growing opiate addiction rates across the world, particularly in the US where new president Donald Trump has declared a national emergency with regard to prescription drug abuse. We look at the underlying trends in this growing space and potential opportunities for investors in the coming years both here in the UK and in the US.
24 Aug 2017
Rude Health
Bioventix Plc (BVXP:LON), 4,450 | OptiBiotix Health PLC (OPTI:LON), 21.0 | Synairgen plc (SNG:LON), 5.2 | Inspiration Healthcare Group PLC (IHC:LON), 28.5 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.6 | SDI Group plc (SDI:LON), 62.5 | Tristel Plc (TSTL:LON), 442
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rude Health
Bioventix Plc (BVXP:LON), 4,450 | OptiBiotix Health PLC (OPTI:LON), 21.0 | Synairgen plc (SNG:LON), 5.2 | Inspiration Healthcare Group PLC (IHC:LON), 28.5 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.6 | SDI Group plc (SDI:LON), 62.5 | Tristel Plc (TSTL:LON), 442
- Published:
24 Aug 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
28
Topic of the quarter: Many recent news articles have highlighted the growing opiate addiction rates across the world, particularly in the US where new president Donald Trump has declared a national emergency with regard to prescription drug abuse. We look at the underlying trends in this growing space and potential opportunities for investors in the coming years both here in the UK and in the US.